Ownership and insider activity for Pliant Therapeutics, Inc. (PLRX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials.
Price
| Price | $1.07 |
| Market Cap | $66M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-09 | Iannone Robert | |||
| 2026-07-09 | Iannone Robert | A-Award | 60,000 | $68K |
| 2026-07-09 | Borellini Flavia | |||
| 2026-07-09 | Borellini Flavia | A-Award | 60,000 | $68K |
| 2026-06-11 | CROWELL GAYLE A | A-Award | 70,000 | $80K |
| 2026-06-11 | MCCOURT Thomas A | A-Award | 70,000 | $80K |
| 2026-06-11 | Krognes Steve E. | A-Award | 70,000 | $80K |
| 2026-06-11 | Curnutte John T | A-Award | 70,000 | $80K |
| 2026-06-11 | Huh Hoyoung | A-Award | 70,000 | $80K |
| 2026-06-11 | Cline Darren S | A-Award | 70,000 | $80K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.3M | $60.9M | $85.8M | $50.9M | $51.7M | $33.7M | $63.2M | $71.2M | $45.4M |
| Short-term Investments | 0 | 0 | $17.0M | $226.0M | $148.9M | $297.5M | $431.0M | $284.5M | $145.5M |
| Receivables | 0 | $500000 | $7.4M | $9.4M | $2.5M | $3.1M | $3.0M | $2.3M | $823000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $4.7M | $61.7M | $111.9M | $290.8M | $209.4M | $340.3M | $505.5M | $362.3M | $196.4M |
| Property, Plant & Equipment | $1.8M | $4.3M | $4.1M | $4.3M | $10.9M | $9.9M | $4.8M | $32.8M | $25.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $6.6M | $66.5M | $119.1M | $295.5M | $221.2M | $350.6M | $512.2M | $396.9M | $225.2M |
| Accounts Payable | $1.6M | $2.6M | $1.2M | $2.0M | $3.0M | $1.6M | $4.5M | $6.0M | $480000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $3.2M | $5.1M | $8.2M | $11.6M | $16.8M | $23.9M | $28.5M | $33.2M | $16.4M |
| Long-term Debt | 0 | $525000 | 0 | 0 | 0 | $9.9M | $10.1M | $30.2M | 0 |
| Total Liabilities | $3.2M | $67.4M | $119.5M | $12.5M | $22.2M | $37.3M | $38.6M | $92.9M | $44.0M |
| Retained Earnings | -$36.6M | -$71.5M | -$76.3M | -$117.8M | -$215.1M | -$338.4M | -$499.7M | -$710.1M | -$859.4M |
| Total Equity | $3.3M | -$882000 | -$435000 | $283.1M | $199.1M | $313.3M | $473.6M | $304.1M | $181.2M |
| Total Debt | 0 | $525000 | $444000 | 0 | $7.2M | $15.8M | $11.4M | $60.2M | $29.1M |
| Net Debt | -$4.3M | -$60.4M | -$102.3M | -$276.9M | -$193.4M | -$315.4M | -$482.9M | -$295.5M | -$161.8M |
| Working Capital | $1.5M | $56.6M | $103.7M | $279.2M | $192.6M | $316.4M | $477.0M | $329.0M | $180.1M |
Financial Health
| Debt / Equity | 0.20 |
| Current Ratio | 9.90 |
Profitability
| Return on Equity | -53.22% |
| Return on Invested Capital | -55.49% |
| Return on Assets | -48.60% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADVM · ARTV · CLNN · COYA · GUTS · MGNX · OVID
Explore sector: Healthcare · Biotechnology
More sections of PLRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks